Back

COVID-19 patients have increased levels of membrane-associated and soluble CD48

Pahima, H.; Zaffran, I.; Ben-Chetrit, E.; Jarjoui, A.; Gaur, P.; Manca, M. L.; Reichmann, D.; Orenbuch-Harroch, E.; Puxeddu, I.; Zinner, C.; Tzankov, A.; Levi-Schaffer, F.

2022-03-19 immunology
10.1101/2022.03.18.484843 bioRxiv
Show abstract

COVID-19 is a respiratory-centered systemic disorder caused by SARS-CoV-2. The disease can progress into a severe form causing acute lung injury. CD48 is a co-signaling receptor, existing as both membrane-bound and soluble forms reported to be dysregulated in several inflammatory conditions. Therefore, we reasoned that CD48 could be deregulated in COVID-19 as well. Here we analyzed CD48 expression in autoptic sections and peripheral blood leukocytes and sera of COVID-19 patients by gene expression profiling (HTG(R) autoimmune panel), immunohistochemistry, flow cytometry and ELISA. Lung tissue of COVID-19 patients showed increased CD48 mRNA expression and infiltration of CD48+ lymphocytes. In the peripheral blood, mCD48 was considerably increased on all evaluated cells, and additionally, sCD48 levels were significantly higher in COVID-19 patients independently of disease severity. Considering the alterations of mCD48 and sCD48, a specific role for CD48 in COVID-19 can be assumed, suggesting it as a potential target for therapy.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.